Research chemicalResearch chemicalDissociative

N-Ethylnorketamine

Also known as NENK · 2-Oxo-PCE · Ethylnorketamine

Written by enwyReviewed 4 Aug 20261 sources0 comments

N-Ethylnorketamine (NENK, 2-oxo-PCE) is a ketamine analogue in which the N-methyl group is replaced by an N-ethyl group. It is a dissociative research chemical acting as an NMDA receptor antagonist, producing ketamine-like dissociation, analgesia and anaesthesia. Human pharmacological data are limited.

01 Overview

N-Ethylnorketamine is one of several ketamine analogues sold as research chemicals. Its effects are reported to resemble ketamine, though potency and duration differ, and formal human data are sparse.

As an NMDA antagonist it produces dose-dependent dissociation and anaesthesia, with the usual dissociative risks of confusion, ataxia and, at high doses, a dissociative 'hole'. Heavy repeated use of ketamine-type dissociatives is associated with urinary tract and cognitive problems, which may plausibly extend to close analogues. Grey-market purity is unreliable.

02 Mechanism

Arylcyclohexylamine NMDA receptor antagonist, reducing glutamatergic excitatory transmission to produce dissociation and anaesthesia.

03 Dosing

Tier	Dose	Route	Notes
Common	20–60 mg	Insufflated	Anecdotal only; potency roughly ketamine-like.
Light	30–70 mg	Oral	Anecdotal.

04 Effects

Effect	Magnitude	Evidence
DissociationKetamine-like detachment from body and environment.		Anecdotal
Analgesia and anaesthesiaReduced pain and numbing at higher doses.		Anecdotal
EuphoriaMood elevation reported at moderate doses.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Psychological dependence and compulsive redosingCraving and dosing sprees reported with ketamine-type dissociatives.	Moderate	Common with heavy use	Anecdotal
Urinary tract toxicity (heavy use)Ketamine-associated cystitis may plausibly extend to close analogues with heavy repeated use.	Severe	Uncommon, heavy chronic use	Unconfirmed
Dissociative anaesthesia and injury riskHeavy dissociation, ataxia and confusion at high doses raise injury and aspiration risk.	Severe	Uncommon, dose-dependent	Anecdotal

06 Legal status

United States

Not scheduled by name

Possible analogue treatment under federal law. · as of Jan 2026

United Kingdom

Psychoactive Substances Act

Covered by blanket psychoactive substances legislation. · as of Jan 2026

07 References

Ketamine analogues as novel dissociatives: a reviewDrug Testing and Analysis

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.